AGP Executive Report
Last update: 2 hours agoDrug Development: Recce Pharmaceuticals signed an exclusive Australia–New Zealand commercialization deal for its Phase 3 diabetic-foot-infection gel, pending regulatory approval. The FDA also approved GSK’s Hibsago for chronic hepatitis B; trials found a functional cure in 19% of treated patients. Drug Costs & Oversight: A new report says median net launch prices climbed 35% to $257,000 in 2025, while researchers found some FDA patient representatives had ties to pharma-funded groups. Care & Technology: A Staten Island high school is preparing a $500,000 studio where students can meet therapists via hologram. Researchers warn harmful chatbot health advice is difficult to track and report. Industry Moves: INTEGRIS Health plans to join Kaiser-backed Risant Health, Abbott will spin off its nutrition business, and OpenAI acquired biotech startup Orchestra Bio to build AI drug-development tools. Pharmacy Access: Walgreens is set to take over prescriptions and customer accounts as century-old Crystal Pharmacy closes, amid warnings that independent pharmacies are struggling to compete.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
